Fred Hutchinson Cancer Center is an independent, nonprofit organization providing adult cancer treatment and groundbreaking research focused on cancer and infectious diseases. Based in Seattle, Fred Hutch is the only National Cancer Institute-designated cancer center in Washington. With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has earned a reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and network affiliations with hospitals in five states. Together, our fully integrated research and clinical care teams seek to discover new cures to the world’s deadliest diseases and make life beyond cancer a reality. At Fred Hutch we value collaboration, compassion, determination, excellence, innovation, integrity and respect. Our mission is directly tied to the humanity, dignity and inherent value of each employee, patient, community member and supporter. Our commitment to learning across our differences and similarities make us stronger. We seek employees who bring different and innovative ways of seeing the world and solving problems. The Barry laboratory, within the Fred Hutchinson Cancer Center’s Translational Research Program, is looking for a talented post-doctoral fellow with extensive expertise in the realm of tumor immunology. The Barry lab focuses on understanding how the immune system responds to cancer and can be manipulated to treat cancer. Our studies utilize human immunology, murine models of cancer, state-of-the-art imaging techniques, RNA sequencing techniques, and immunological techniques to explore the role of the innate immune system in controlling immune responses to cancer. We focus our research on understanding how the innate immune system, specifically dendritic and natural killer cells, shape immune responses to cancer and patient responses to common immunotherapies (see PMID: 29942093, PMID: 33613552, and PMID: 32690952).